MTD · Mettler Toledo International Inc/
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $20.35 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted free cash flow non-GAAP | $366.72M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Operating Profit non-GAAP | $309.3M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Earnings before taxes 289.4M
-24.55M One-time tariff refunds, net
+19.43M Amortization
+17.25M Interest expense
+5.45M Restructuring charges
+2.37M Other charges (income), net
= Adjusted Operating Profit 309.34M
|
|||
| Local Currency Sales Growth non-GAAP | 6% | Q2 2026 | — |
|
|
|||
| Local Currency Sales Growth excluding acquisitions non-GAAP | 4% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTD
this stock
Mettler Toledo International Inc/
|
$28.43B | +1.8% | +4.0% | 32.0 | 3.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$222.96B | +1.5% | +14.5% | 32.4 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTD | -0.7% | +8.3% | +1.9% | +0.2% | +1.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.1% | +3.9% | -11.9% | -3.7% | -12.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.